Present medical use of Rx stimulants for ADHD up in teens from 2005 to 2023

Among united state teenagers, existing clinical use prescription stimulants for attention-deficit/hyperactivity condition (ADHD) increased in between 2005 and 2023, while nonmedical use lowered, according to a research letter published online July 29 in the JAMA

Sean Esteban McCabe, Ph.D., from the University of Michigan in Ann Arbor, and colleagues checked out trends in clinical and nonmedical prescription energizer usage patterns for ADHD among united state teens. The analysis included data from 259, 623 pupils (eighth, 10 th, and 12 th grades) participating in the Keeping an eye on the Future research study (2005 to2023

The researchers located that life time clinical use of prescription stimulants for ADHD came to a head in 2022 at 9 30 %. There was a direct, nonsignificant pattern. The lowest point for life time nonmedical usage was 4 69 % in 2023, with a considerable reduction over time (readjusted probabilities ratio [aOR] straight fad, 0.971 For present clinical use of prescription energizers, the top was in 2022 at 4 46 %, with small boosts in time (aOR direct pattern, 1016

Among participants with present clinical usage, 14 5 % had used prescription energizers for much less than one year, 18 6 % for one to two years, and 66 9 % for 3 years or longer. With time, existing medical and nonmedical co-use lowered (aOR straight fad , 0.980 Participants in 10 th and 12 th quality had a better occurrence of nonmedical use of prescription energizers yet additionally experienced greater decreases in nonmedical usage in time.

“Regardless of issues regarding boosted energizer prescribing, findings suggest no involved boost in nonmedical prescription stimulant use at this time, although longitudinal research and proceeded tracking is essential,” the writers write.

One writer disclosed ties to relevant companies.

© 2025 HealthDay All rights booked.